

<b>Name of the Issue: Akums Drugs and Pharmaceuticals Limited</b>			
<b>1</b>	<b>Type of Issue</b>	Initial Public Offer	
<b>2</b>	<b>Issue Size (Rs. Mn)</b>	18567.37*	
*Source: Prospectus dated August 1, 2024			
<b>3</b>	<b>Grade of issue along with name of the rating agency</b>		
	<b>Name</b>	NA	
	<b>Grade</b>	NA	
<b>4</b>	<b>Subscription Level (Number of times)</b>	64.64*	
* excluding Anchor Investor Portion and after removing multiple and duplicate bids			
Source: Minutes for basis of allotment dated August 2, 2024			
<b>5</b>	<b>QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges</b>		
	<b>Particulars</b>	<b>%</b>	
	(i) On Allotment **	12.92	
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2024)	14.86	
	(iii) at the end of 1st FY (March 31, 2025)	13.17	
	(iv) at the end of 2nd FY (March 31, 2026)*	Not Available	
	(v) at the end of 3rd FY (March 31, 2027)*	Not Available	
**Basis of Allotment (excluding pre-issue QIB holding)			
* QIB Holding not disclosed as reporting for relevant period has not been completed.			
<b>6</b>	<b>Financials of the issuer</b>	<i>in Millions</i>	
	<b>Parameters</b>	<b>1st FY (March 31,2025)</b>	<b>2nd FY (March 31,2026)*</b>
		<b>3rd FY (March 31,2027)*</b>	
	Income from operations	41,181.58	Not Available
	Net Profit/(Loss) for the period	3,437.77	Not Available
	Paid-up equity share capital	306.21	Not Available
	Reserves excluding revaluation reserves	30,163.93	Not Available
* Financials not available as reporting for the relevant years has not been completed.			
<b>7</b>	<b>Trading Status</b>		
The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")			
The equity shares have not been suspended or delisted.			
	<b>Particulars</b>	<b>Status</b>	
	(i) at the end of 1st FY (March 31, 2025)	Frequently	
	(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	
* Trading status not disclosed as the relevant fiscal years have not been completed.			
<b>8</b>	<b>Change in Directors of Issuer from the disclosures in the offer document</b>		
	<b>Particulars</b>	<b>Name of Director</b>	<b>Appointed / Resigned</b>
	(i) at the end of 1st FY (March 31, 2025)	Mr. Nand Lal Kalra	Cessation due to attaining age
	(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available
* Changes in Directors of Issuer not updated as the relevant financial years have not been completed			

<b>9 Status of implementation of project/ commencement of commercial production</b>	
(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

**10 Status of utilization of issue proceeds**

(i) as disclosed in the offer document

Particulars	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2025	Estimated Utilisation of Net Proceeds in Fiscal 2026 and beyond
Repayment/ prepayment of indebtedness of the Company	1599.10	1599.10	0.00
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2270.90	-	2270.90
Funding incremental working capital requirements of our Company	550.00	-	550.00
Pursuing inorganic growth initiatives through acquisitions	278.70	-	278.70
General corporate purposes	1675.00	-	1675.00
<b>Total Proceeds</b>	<b>6373.70</b>	<b>1599.10</b>	<b>4774.60</b>

(ii) Actual implementation

Particulars	Amount proposed to be financed from Net Proceeds	Actual Utilisation of Net Proceeds	Unutilised Net Proceeds
Repayment/ prepayment of indebtedness of the Company	1599.10	1599.10	0.00
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2270.90	2270.90	0.00
Funding incremental working capital requirements of our Company	550.00	550.00	0.00
Pursuing inorganic growth initiatives through acquisitions	278.70	278.70	0.00
General corporate purposes	1675.00	1675.00	0.00
<b>Total Proceeds</b>	<b>6373.70</b>	<b>6373.70</b>	<b>0.00</b>

Source: Monitoring Agency Report dated August 11 2025

(iii) Reasons for delay in implementation, if any Not applicable

**11 Comments of monitoring agency, if applicable**

(i) Comments on use of funds	Nil
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Nil
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Nil

**12 Pricing Data**

Designated Stock Exchange	NSE					
Issue Price (Rs.)	679.00					
Listing Date	6-Aug-24					
Price parameters	At close of listing day August 06, 2024	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2025)		
				Closing price	High	Low
Market Price	679.00	855.25	845.3	471.1	480.5	466.0
Nifty 50*	23,992.55	25,418.55	23,995.35	23,165.70	23,565.15	23,136.40
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2026) <sup>(1)</sup>			As at the end of the 3rd FY after the listing of the issue (31st March, 2027) <sup>(1)</sup>		
	Closing price	High	Low	Closing price	High	Low
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

\* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

**13 Basis for Issue Price**

Accounting ratio		Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)	At the end of 1st FY (March 31,2026)**	At the end of 1st FY (March 31,2027)**	
EPS (Diluted)	<b>Company Consolidated</b>	2	-0.28	22.60	Not Available	Not Available	
	<b>Peer Group:</b>						
	Divi's Laboratories	2	60.27	83.20			
	Suven Pharma (Now Cohance Lifesciences)	1	11.8	10.45	Not Available	Not Available	
	Gland Pharma	1	46.89	42.40	Not Available	Not Available	
	Torrent Pharma	5	48.94	56.47	Not Available	Not Available	
	Alkem Laboratories	2	150.19	181.11	Not Available	Not Available	
	Eris Lifesciences	1	28.79	25.81	Not Available	Not Available	
	JB Chemicals	1	34.85	41.56	Not Available	Not Available	
	Mankind Pharma	1	47.68	49.08	Not Available	Not Available	
	Innova Captab	10	18.66	22.41	Not Available	Not Available	
	<b>Industry Avg</b>		49.79	56.94	Not Available	Not Available	
	P/E	<b>Company Consolidated</b>	2	NA	20.84	Not Available	Not Available
		<b>Peer Group:</b>					
Divi's Laboratories		2	74.99	66.69	Not Available	Not Available	
Suven Pharma (Now Cohance Lifesciences)		1	69.54	102.82	Not Available	Not Available	
Gland Pharma		1	42.45	36.68	Not Available	Not Available	
Torrent Pharma		5	60.2	56.34	Not Available	Not Available	
Alkem Laboratories		2	34.18	26.69	Not Available	Not Available	
Eris Lifesciences		1	34.95	53.89	Not Available	Not Available	
JB Chemicals		1	51.38	37.30	Not Available	Not Available	
Mankind Pharma		1	44.65	50.06	Not Available	Not Available	
Innova Captab		10	29.91	39.76	Not Available	Not Available	
<b>Industry Avg</b>			49.14	52.25	Not Available	Not Available	
RoNW		<b>Company Consolidated</b>	2	-0.57%	11.28%	Not Available	Not Available
		<b>Peer Group:</b>					
	Divi's Laboratories	2	11.79%	14.83%	Not Available	Not Available	
	Suven Pharma (Now Cohance Lifesciences)	1	14.64%	15.61%	Not Available	Not Available	
	Gland Pharma	1	8.85%	7.63%	Not Available	Not Available	
	Torrent Pharma	5	24.15%	25.17%	Not Available	Not Available	
	Alkem Laboratories	2	17.41%	18.48%	Not Available	Not Available	
	Eris Lifesciences	1	15.16%	11.45%	Not Available	Not Available	
	JB Chemicals	1	18.90%	19.21%	Not Available	Not Available	
	Mankind Pharma	1	20.43%	14.03%	Not Available	Not Available	
	Innova Captab	10	11.35%	13.37%	Not Available	Not Available	
	<b>Industry Avg</b>		15.85%	15.53%	Not Available	Not Available	
	NAV per share	<b>Company Consolidated</b>	2	49.59	193.59	Not Available	Not Available
		<b>Peer Group:</b>					
Divi's Laboratories		2	511.21	561.08	Not Available	Not Available	
Suven Pharma (Now Cohance Lifesciences)		1	80.56	44.35	Not Available	Not Available	
Gland Pharma		1	529.65	555.41	Not Available	Not Available	
Torrent Pharma		5	202.57	224.29	Not Available	Not Available	
Alkem Laboratories		2	862.46	1,002.37	Not Available	Not Available	
Eris Lifesciences		1	190.12	240.28	Not Available	Not Available	
JB Chemicals		1	188.37	220.54	Not Available	Not Available	
Mankind Pharma		1	233.73	347.39	Not Available	Not Available	
Innova Captab		10	145.2	167.66	Not Available	Not Available	
<b>Industry Avg</b>			327.10	373.71	Not Available	Not Available	

Notes

\* Sourced from Prospectus dated August 01, 2024.

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

**14 Any other material information**

Particulars	Date	Remarks
		Not Applicable

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com